Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What is the Forecasted Expansion Rate of the Cancer Biopsy Market Over the 2025–2034 Period?

The market for cancer biopsies has experienced swift growth in recent years, with projections showing an increase from $25.08 billion in 2024 to $28.52 billion in 2025. This growth, indicating a compound annual growth rate (CAGR) of 13.7%, can be traced back to factors such as heightened awareness of liquid biopsy procedures for breast cancer, a rise in awareness surrounding inherited oncology diseases and genetic testing, a growing acceptance of liquid biopsies, and an increase in the demand for both minimally invasive biopsy treatments and tissue biopsies.

Anticipations are high for exponential growth in the cancer biopsy market size in the forthcoming years. The projections estimate a swelling to $47.2 billion by 2029, boasting a compound annual growth rate (CAGR) of 13.4%. The considerable growth in this period can be linked to a rise in patient numbers, an increasing aging population, an upwards surge in suspicions of breast cancer cases, a general increase in cancer incidences, and a rise in diagnosis and biopsy testing frequency. Significant forecast period trends that could contribute include the progress in technology, the application of artificial intelligence and machine learning, the introduction and integration of multi-omics, innovative products, and point-of-care biopsy devices.

What External and Internal Drivers Are Contributing to the Growth of the Cancer Biopsy Market’s Growth?

The escalating occurrence of cancer is likely to fuel the expansion of the cancer biopsy market in the future. Cancer encompasses a range of conditions marked by abnormal cell growth and distribution. The escalating incidence of cancer is attributable to multiple factors, including lifestyle alterations and urbanization, environmental pollution, tobacco and alcohol use, healthcare accessibility, and awareness. A cancer biopsy is employed to diagnose and evaluate the type, stage, and spread of cancer by extracting and examining tissues or cells from a dubious area. For example, in January 2023, the National Center for Biotechnology Information, a US intergovernmental organization, reported 1,958,310 novel cancer cases and 609,820 cancer-related deaths in the United States. Additionally, in May 2021, the National Library of Medicine, a US medical library, projected that the global cancer burden is set to reach 28.4 million cases by 2040, marking a 47% surge from 2020 accompanied by a high death toll. Consequently, the mounting occurrence of cancer is a key driver of the cancer biopsy market.

Get Your Free Sample of the Global Cancer Biopsy Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=19355&type=smp

Who Are the Leading Organizations Fueling the Expansion of the Cancer Biopsy Market?

Major companies operating in the cancer biopsy market are Thermo Fisher Scientific Inc., Danaher Corporation, Becton Dickinson and Company, Roche Diagnostics GmbH, Hologic Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Exact Sciences Corporation, Myriad Genetics Inc., Guardant Health Inc., Veracyte Inc., GRAIL Inc., Freenome Holdings Inc., Biodesix Inc., Chronix Biomedical Inc., Biocept Inc., Personal Genome Diagnostics Inc., Agena Bioscience Inc., Oncimmune Holdings plc, Exosome Diagnostics Inc., Epigenomics AG, Genesystems Inc., Lucence Diagnostics Pte. Ltd., ANGLE plc

Which Cutting-Edge Trends Are Expected to Drive the Cancer Biopsy Market’s Growth?

Major corporations in the cancer biopsy market, such as Labcorp, are pioneering liquid biopsy methods as a way to improve and personalize cancer treatment by enabling non-invasive early detection and disease tracking. The cutting-edge liquid biopsy process uses a simple blood sample to detect and study genetic material, including circulating tumor DNA, RNA, exosomes, and additional biomarkers. Labcorp, a leading US manufacturer of cancer biopsies, released Labcorp Plasma Focus in May 2023: a liquid biopsy specializing in plasma for the identification of cancer-related biomarkers. This Plasma Focus assay scrutinizes circulating cell-free DNA from tumor cells found in the bloodstream and establishes a genomic layout of the patient’s tumor. It can pinpoint mutations in 33 genes connected to a variety of cancer types like non-small cell lung cancer, colorectal cancer, breast cancer, esophageal cancer, and melanoma.

Get Instant Access to the Global Cancer Biopsy Market Report with Swift Delivery!

https://www.thebusinessresearchcompany.com/report/cancer-biopsy-global-market-report

What Are the Core Categories and Segments in the Cancer Biopsy Market Driving Demand and Growth?

The cancer biopsymarket covered in this report is segmented –

1) By Type: Tissue Biopsies, Liquid Biopsies, Other Types

2) By Application: Breast Cancer, Colorectal Cancer, Cervical Cancers, Lung Cancers, Prostate Cancers, Skin Cancers, Blood Cancers, Kidney Cancers, Other Applications

3) By End User: Hospitals, Diagnostic Laboratories, Other End Users

Subsegments:

1) By Tissue Biopsies: Core Needle Biopsies, Fine Needle Aspiration (FNA) Biopsies, Incisional Biopsies, Excisional Biopsies

2) By Liquid Biopsies: Circulating Tumor Cell (CTC) Analysis, Circulating Tumor DNA (ctDNA) Testing, Plasma Biomarker Testing

3) By Other Types: Bone Biopsies, Endoscopic Biopsies, Brush Biopsies, Skin Biopsies

Which Regions Are Most Influential in Expanding the Cancer Biopsy Market?

North America was the largest region in the cancer biopsy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer biopsy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Parameters Define the Cancer Biopsy Market’s Scope?

A cancer biopsy is a medical procedure that involves the removal of a small sample of tissue or cells from a suspicious area of the body to determine the presence of cancer or other conditions. This procedure is essential for diagnosing cancer, as imaging tests such as computed tomography (CT) scans or magnetic resonance imaging (MRI) cannot definitively differentiate between cancerous and non-cancerous cells.

Browse Through More Similar Reports By The Business Research Company:

Cancer Diagnostics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Pancreatic Cancer Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-drugs-global-market-report

Blood Cancer Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: